The treatment of elderly patients with chronic lymphocytic leukemia and comorbid conditions requires an assessment of individual patient factors an......READ MORE
Noncovalent BTK inhibitors (eg, pirtobrutinib) have generated promising data in the later-line treatment of chronic lymphocytic leukemia (CLL). Piv......READ MORE
by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD
Although active surveillance may cause anxiety among patients, the treatment of asymptomatic, early-stage chronic lymphocytic leukemia (CLL) is not......READ MORE
by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD
Trends in the frontline treatment of chronic lymphocytic leukemia (CLL) include the widespread use of Bruton tyrosine kinase (BTK) inhibitor therap......READ MORE
Minimal residual disease (MRD) is a sensitive indicator of disease burden in chronic lymphocytic leukemia (CLL). While MRD analysis is becoming mor......READ MORE
Older patients with chronic lymphocytic leukemia (CLL) have more options for well-tolerated treatment than in the past. Planning treatment involves......READ MORE